secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193125-23-135073
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q1 net loss narrows to $140M ($0.92 loss per share); cash $467M after $150M offering
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $140.2M ($0.92 diluted EPS) vs $196.4M ($1.35) in Q1 2022; revenue $1.8M flat.
- Operating expenses fell 27% YoY to $128.0M from $175.4M, reflecting cost restructuring and program reprioritization.
- Cash, equivalents, marketable securities, and restricted cash $467.0M; includes $143M net from follow-on offering closed in March 2023.
- Phase 3 ATTR-CM trial of acoramidis completed last patient last visit; topline month-30 data expected late July 2023.
- Infigratinib (achondroplasia) Phase 2 Cohort 5 showed +3.03 cm/yr annualized height velocity; 80% responders; Phase 3 run-in started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/0001193125-23-135073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/d207223d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-135073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer